We compared glycoprotein E (gE)- and varicella zoster virus (VZV)-specific Th1 immunity in 160 adults, aged 50-85 years, randomized to receive live or recombinant zoster vaccine (RZV). gE-specific responses measured by interferon-γ (IFN-γ) and interleukin 2 (IL-2) dual-color Fluorospot were significantly higher at all time points postimmunization in RZV recipients. VZV-specific IL-2+ memory, but not IFN-γ+ or IFN-γ+IL-2+ effector responses, were higher in RZV recipients at ≥3 months postimmunization. Only RZV recipients maintained higher postvaccination gE-specific IL-2+ and IFN-γ+ and VZV-specific IL-2+ responses for 5 years. The 5-year persistence of VZV-specific memory and gE-specific Th1 immunity may underlie superior RZV efficacy. Clinical Trials Registration NCT02114333.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016444 | PMC |
| http://dx.doi.org/10.1093/infdis/jiab580 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Post-Marketing Surveillance of Adverse Events for the Recombinant Zoster Vaccine Among the Population over 50 Years Old in Hangzhou, China.
Vaccines (Basel)
December 2024
Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou 310021, China.
Objectives: This study aimed to evaluate the safety profile of the recombinant zoster vaccine (RZV) after its marketing in China.
Methods: We present a descriptive analysis and safety signal assessment of adverse events following immunization (AEFI) associated with RZV between September 2020 and December 2023. The descriptive data collected includes demographic characteristics and the classification of characteristics of AEFI cases, while vaccine safety signal assessment was evaluated using the reporting odds ratio (ROR).
Using Double Negative Controls to Adjust for Healthy User Bias in a Recombinant Zoster Vaccine Safety Study.
Am J Epidemiol
November 2024
Department of Biostatistics, University of Michigan.
Unmeasured confounding is a major concern in many epidemiologic studies that are not randomized. Negative control methods can detect and reduce confounding by leveraging the proxies of the unmeasured confounders, including negative control outcomes (NCO) and exposures (NCE). An NCO is presumably unaffected by the exposure of interest but would be associated with unmeasured confounders; an NCE presumably does not affect the outcome of interest but would be associated with unmeasured confounders.
View Article and Find Full Text PDFSystematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations.
PLoS One
November 2024
Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Article Synopsis
- Herpes zoster is a common infection that poses significant risks to immunocompromised individuals, leading to a recommendation for the recombinant zoster vaccine (RZV).
- A systematic review of studies found that RZV is highly effective, reducing herpes zoster incidence by 81% in immunocompromised adults while boosting immunity one month after vaccination.
- Although RZV was associated with increased local and systemic side effects, there were no notable differences in serious adverse events or death rates compared to placebo, indicating it is generally safe for use in this population.
Safety of Adjuvanted Recombinant Herpes Zoster Virus Vaccination in Fragile Populations: An Observational Real-Life Study.
Vaccines (Basel)
August 2024
Department of Medicine, Surgery, and Dentistry, University of Salerno, 84081 Baronissi, Italy.
Background: Vaccination is the most effective strategy for preventing infectious diseases and related complications, and proving its efficacy is crucial for its success and adherence, especially for newly introduced vaccines, such as adjuvanted recombinant herpes zoster virus vaccination (RZV). In this observational real-life study, we recorded adverse effects following immunization (AEFIs) after RZV administration in frail populations.
Methods: A total of 271 subjects underwent RZV at Vaccination Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.
Hum Vaccin Immunother
December 2023
Molecular Virology Unit, Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Herpes zoster (HZ) is caused by the reactivation of latent varicella zoster virus (VZV). Severe immunocompromising conditions, such as solid tumors, have been largely associated with an increased risk for HZ due to waning VZV-specific cellular immunity. With the approval of the adjuvanted glycoprotein E (gE)-based recombinant vaccine (RZV; Shingrix™, GSK) also in immunocompromised subjects, HZ is considered a vaccine-preventable disease changing perspectives in immunocompromised subjects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!